Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy
NCT ID: NCT00107796
Last Updated: 2012-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
140 participants
INTERVENTIONAL
2004-10-31
2005-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* mean sleep latency from the Multiple Sleep Latency Test (MSLT) (average of 4 naps performed at 0900, 1100, 1300, and 1500) at the last post-baseline observation (week 6 or early termination)
* the Clinical Global Impression of Change (CGI-C) ratings for ES, at the last post-baseline observation (week 6 or early termination).
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Modafinil
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent/assent is obtained
* A boy or girl aged 6 through 16 years, inclusive
* Meet the minimal criteria established by the International Classification of Sleep Disorders (ICSD) manual of the American Academy of Sleep Medicine (AASM) for narcolepsy (or presumed narcolepsy) as assessed by all of the following: \*clinical history;
* NPSG (nocturnal polysomnogram) (as evaluated by the investigator) to rule out other sleep disorders (ie, obstructive sleep apnea/hypopnea syndrome \[OSAHS\] or periodic limb movement with sleep \[PLMs\]);
* narcolepsy (or presumed narcolepsy) as identified by at least 1 of the following: MSLT (as evaluated by the investigator) (mean sleep latency \[from 4 naps\] \<10 minutes); 2 sleep onset REM periods (SOREMP); cataplexy; sleep paralysis; hypnogogic hallucinations -OR- \*have a previous diagnosis of narcolepsy on the basis of NPSG and/or MSLT at any time before the screening visit
* Have ES (MSLT \<10 minutes and/or CGI S ≥4) that is not a direct result of inadequate sleep hygiene or other medical disorder
* Are in good health as determined by a medical and psychiatric history, physical examination, ECG, and clinical laboratory tests
* Have blood pressure values greater than those for the 5th percentile and less than the 95th percentile for age on the National High Blood Pressure Education Program guidelines for blood pressure levels for boys and girls ages 6 through 16 years
* Girls who are post menarche or sexually active must have a negative urine pregnancy test prior to the baseline visit, must be using a medically acceptable method of birth control, and must agree to continue use of this method for the duration of the study (and for 30 days after participation in the study). Acceptable methods of birth control include: barrier method with spermicide; steroidal contraceptive (eg, oral, transdermal, implanted, or injected) in conjunction with a barrier method; intrauterine device (IUD); or abstinence.
* Be able to swallow a placebo tablet the same size and shape as the study drug tablet
* Negative UDS (urine drug screen) for any illicit drug, alcohol (ethanol), stimulants, or modafinil at screening; if positive for stimulants or modafinil (prescribed for ES) at the screening visit, UDS to be repeated after a washout period and before the baseline visit
* Have a parent or legal guardian who is willing to participate in the study
Exclusion Criteria
* Have any other disorder(s) that could be considered the primary cause of ES (eg, self induced sleep deprivation)
* Have a past or present seizure disorder (except history of a single febrile seizure), a history of psychosis, or of clinically significant head trauma (eg, brain damage) or past neurosurgery
* Have a history of suicide attempt, or are at suicidal risk
* Have an average of 5 or more apneic/hypopneic episodes per hour of nocturnal sleep as assessed by NPSG at the baseline visit
* A clinically significant drug sensitivity to stimulants such as amphetamine, dextroamphetamine, methylphenidate, or pemoline; and/or modafinil or any of its components
* Use of any prescription (eg, clonidine, guanfacine) or nonprescription (over the counter \[OTC\]) medications, including dietary supplements with psychoactive properties (eg, any OTC medications or supplements containing ephedrine \[ie, ma huang or ephedra\], pseudoephedrine, caffeine, or phenylpropanolamine) or sedating properties (ie, antihistamines or sedative hypnotics) within 1 week of the baseline visit (Note: Medications for the treatment of cataplexy will be permitted if the patient has been on a stable dose for at least 1 month.)
* Use of any MAO (monoamine oxidase) inhibitors or SSRIs (Selective Serotonin Reuptake Inhibitors) within 2 weeks of the baseline visit (unless used for cataplexy)
* Received any investigational drug (except modafinil) within 4 weeks of the baseline visit
* Any disorder that could interfere with drug absorption, distribution, metabolism, or excretion (including previous gastrointestinal surgery)
* Active, clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematologic, neoplastic, endocrine, neurologic, immunodeficiency, pulmonary, or other major clinically significant disorder/disease
* Any clinically significant deviation from the normal range(s) in the physical examination or ECG findings, or clinical laboratory test results (ie, serum chemistry, hematology, and urinalysis) at the screening or baseline visit
* ANC (absolute neutrophil count) below the lower limit of normal at the screening visit (Note: If the ANC is below the lower limit of normal at the baseline visit, the medical monitor will be consulted for continued eligibility in the study.)
* Seated pulse outside the range of 60 through 115 bpm after resting for 5 minutes
* A history of alcohol, narcotic, or any other substance abuse or dependence as defined by the Diagnostic and Statistical Manual of the American Psychiatric Association, 4th Edition (DSM IV) criteria
* A total daily intake of more than 250 mg of caffeine per day (eg, approximately five 12 ounce caffeinated sodas, 2.5 cups of coffee or tea, or about 12.5 ounces of chocolate per day) within 1 week of the baseline visit
* Pregnant or lactating/nursing girl; any girl who becomes pregnant during the study will be withdrawn
* A clinically significant illness within 4 weeks of the baseline visit; or is symptomatic for any clinically significant illness at the screening or baseline visit
6 Years
16 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cephalon
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Robert Doekel, Jr., M.D.
Birmingham, Alabama, United States
Chris M. Makris, M.D.
Birmingham, Alabama, United States
Barbara Harris, Ph.D.
Phoenix, Arizona, United States
Derek Loewy, Ph.D.
Tucson, Arizona, United States
Stuart Quan, M.D.
Tucson, Arizona, United States
Joseph McCarty, M.D.
Fort Smith, Arkansas, United States
John L. Carroll, M.D.
Little Rock, Arkansas, United States
Samuel Boellner, M.D.
Little Rock, Arkansas, United States
Julie Thompson-Dobkin, D.O.
Huntington Beach, California, United States
Mark Buchfuhrer, M.D.
Long Beach, California, United States
Yury Furman, M.D.
Los Angeles, California, United States
Stuart Menn, M.D.
Palm Springs, California, United States
Richard Shubin, M.D.
Pasadena, California, United States
Lawrence Sher, M.D.
Rolling Hills Estates, California, United States
Milton K. Erman, M.D.
San Diego, California, United States
Stephen Brooks, M.D.
San Francisco, California, United States
Paul Haberman, M.D.
Santa Monica, California, United States
Jed Black, M.D.
Stanford, California, United States
Amerigo Padilla, M.D.
Miami, Florida, United States
Martin A. Cohn, M.D.
Naples, Florida, United States
D. Alan Lankford, Ph.D.
Atlanta, Georgia, United States
Gary Montgomery, M.D.
Atlanta, Georgia, United States
Jerry Silverboard, M.D.
Atlanta, Georgia, United States
Charles Wells, Jr., M.D.
Macon, Georgia, United States
Stephen H. Sheldon, D.O., FAAP
Chicago, Illinois, United States
Michael Kohrman, M.D.
Chicago, Illinois, United States
Anna Ivanenko, M.D., Ph.D.
Maywood, Illinois, United States
Henry Lahmeyer, M.D.
Northfield, Illinois, United States
James Cook, M.D.
Danville, Indiana, United States
William Leeds, D.O.
Topeka, Kansas, United States
Karen Waters, M.D.
Louisville, Kentucky, United States
Margaret Ann Springer, M.D.
Shreveport, Louisiana, United States
Helene A. Emsellem, M.D.
Chevy Chase, Maryland, United States
Marc Raphaelson, M.D.
Frederick, Maryland, United States
Daniela Minecan, M.D.
Ann Arbor, Michigan, United States
George Zureikat, M.D.
Flint, Michigan, United States
John Harsh, Ph.D., DABSM
Hattiesburg, Mississippi, United States
Pradeep Sahota, M.D.
Columbia, Missouri, United States
William Torch, M.D., MS
Reno, Nevada, United States
Kathleen Ryan, M.D.
Mount Laurel, New Jersey, United States
Sushmita Mikkilineni, M.D.
New Brunswick, New Jersey, United States
Monroe Karetzky, M.D.
Newark, New Jersey, United States
Lee Brooks, M.D.
Princeton, New Jersey, United States
Marc Seelagy, M.D.
Trenton, New Jersey, United States
Gary Zammit, M.D.
New York, New York, United States
James Lee, M.D.
Charlotte, North Carolina, United States
Bruce Corser, M.D.
Cincinnati, Ohio, United States
Raouf Amin, MD
Cincinnati, Ohio, United States
Martin Scharf, Ph.D.
Cincinnati, Ohio, United States
Carol Rosen, M.D.
Cleveland, Ohio, United States
Markus H. Schmidt, M.D., Ph.D.
Dublin, Ohio, United States
Michael Neeb, Ph.D.
Toledo, Ohio, United States
William C. Orr, Ph.D.
Oklahoma City, Oklahoma, United States
Jorg Pahl, M.D.
Oklahoma City, Oklahoma, United States
Dainis Irbe, M.D.
Eugene, Oregon, United States
William Pistone, M.D.
Allentown, Pennsylvania, United States
Jeffery Gould, M.D.
Bethlehem, Pennsylvania, United States
Guillermo Borrero, M.D.
Clairton, Pennsylvania, United States
Lee Brooks, M.D.
Philadelphia, Pennsylvania, United States
Judith Owens, M.D., MPH
Providence, Rhode Island, United States
Richard Bogan, M.D., FCCP
Columbia, South Carolina, United States
Julie Jacques, D.O.
Morristown, Tennessee, United States
John Hudson, M.D.
Austin, Texas, United States
David Sperry, M.D.
Dallas, Texas, United States
Todd J. Swick, M.D.
Houston, Texas, United States
Jerry J. Tomasovic, M.D.
San Antonio, Texas, United States
James M. Ferguson, M.D.
Salt Lake City, Utah, United States
Ralph A. Pascualy, M.D.
Seattle, Washington, United States
Adam Moscovitch, M.D.
Calgary, Alberta, Canada
Leonid Kayumov, M.D.
Scarborough Village, Ontario, Canada
Mortimer Mamelak, M.D.
Toronto, Ontario, Canada
Colin Shapiro, Ph.D.
Toronto, Ontario, Canada
Allen Denys, M.D.
Windsor, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C1538/3027/NA/MN-Narcolepsy
Identifier Type: -
Identifier Source: org_study_id